Polar Capital's Douglas 'optimistic' on defensive healthcare
Eye on large-cap pharma and biotech
Large-cap biotech firms can display "defensive characteristics through the Covid-19 crisis", according to Douglas
Defensive areas within healthcare provide nuggets of optimism, with large-cap pharmaceuticals and large-cap biotechnology particularly favoured, Polar Capital has said.
James Douglas, fund manager within the global healthcare team, said large-cap pharma and biotech have collective strong balance sheets, good cashflow conversation and secure dividend yields, where applicable....
More on Funds
Back to Top
